These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 29103946

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 23. Relationship between spine osteoarthritis, bone mineral density and bone turn over markers in post menopausal women.
    Ichchou L, Allali F, Rostom S, Bennani L, Hmamouchi I, Abourazzak FZ, Khazzani H, El Mansouri L, Abouqal R, Hajjaj-Hassouni N.
    BMC Womens Health; 2010 Aug 08; 10():25. PubMed ID: 20691114
    [Abstract] [Full Text] [Related]

  • 24. Characteristics of biochemical markers in patients with metabolic bone disorders.
    Hoshino H, Kushida K, Takahashi M, Kawana K, Denda M, Yamazaki K, Inoue T.
    Endocr Res; 1998 Feb 08; 24(1):55-64. PubMed ID: 9553754
    [Abstract] [Full Text] [Related]

  • 25. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K, Kassem M, Nielsen HK, Loft AG, Flyvbjerg A, Mosekilde L.
    J Bone Miner Res; 1995 Dec 08; 10(12):1865-74. PubMed ID: 8619366
    [Abstract] [Full Text] [Related]

  • 26. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M, Fukunaga M, Ohtawa T, Harada T.
    World J Surg; 1996 Sep 08; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A dual-label time-resolved fluorescence immunoassay for screening of osteoporosis based on simultaneous detection of C-terminal telopeptide (β-CTX) and aminoterminal propeptide (P1NP) of type I procollagen.
    Xu Y, Wang Q, Hou G, Yao H, Zhao H.
    Scand J Clin Lab Invest; 2019 Sep 08; 79(1-2):80-85. PubMed ID: 30638079
    [Abstract] [Full Text] [Related]

  • 31. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R, Blumsohn A, Naylor K, Eastell R.
    J Bone Miner Res; 1998 Jul 08; 13(7):1124-33. PubMed ID: 9661076
    [Abstract] [Full Text] [Related]

  • 32. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL, Loft AG, Møller N, Weeke J, Eriksen EF, Mosekilde L, Charles P.
    J Bone Miner Res; 1997 Jan 08; 12(1):78-88. PubMed ID: 9240729
    [Abstract] [Full Text] [Related]

  • 33. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec 08; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 34. Changes of bone turnover markers after elderly hip fracture surgery.
    Li XP, Li XY, Yang MH, Zhu SW, Wu XB, Zhang P.
    J Bone Miner Metab; 2021 Mar 08; 39(2):237-244. PubMed ID: 32876727
    [Abstract] [Full Text] [Related]

  • 35. [Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis].
    Bahlous A, Kalai E, Hadj Salah M, Bouzid K, Zerelli L.
    Tunis Med; 2006 Nov 08; 84(11):751-7. PubMed ID: 17294906
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 08; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Mineral bone disorder and osteoporosis in hemodialysis patients.
    Slouma M, Sahli H, Bahlous A, Laadhar L, Smaoui W, Rekik S, Gharsallah I, Sallami M, Moussa FB, Elleuch M, Cheour E.
    Adv Rheumatol; 2020 Feb 26; 60(1):15. PubMed ID: 32102689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.